Frequent Monitoring of Blood Glucose Levels via a Remote Patient Monitoring System Helps Improve Glycemic Control |
| |
| Institution: | 1. Department of Endocrinology, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, Queens, New York;2. Department of Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, Queens, New York;3. New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York;1. Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, China;2. Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China;1. Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China;2. The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China;1. Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA;2. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA;3. Geriatric Research Education and Clinical Center, VA Health Care System, Minneapolis, MN;4. Department of Medicine, University of California, Irvine, CA;5. Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA;6. Division of Endocrinology, Kaiser Permanente of Georgia, and Department of Endocrinology, Emory University School of Medicine, Atlanta, GA;1. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland;2. Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida;3. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, Maryland;4. Section on Hospital Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina;5. Center for Prevention of Cardiovascular Disease, Section on Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina;1. Endocrinology and Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México;2. Clinical Epidemiology Unit, Hospital Infantil Federico Gómez, Mexico City, México;3. Clinical Epidemiology Unit, UMAE, Hospital de Especialidades Centro Medico Siglo XXI, IMSS, Mexico City, México;4. Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México |
| |
| Abstract: | ObjectiveThis study aimed to evaluate the effectiveness of the Vivovitals diabetes platform in improving glycemic control and reducing hemoglobin A1c (HbA1c) levels in patients with uncontrolled type 2 diabetes mellitus by providing more accessible and direct patient care under the monitoring and oversight of their physician.MethodsThis 12-week, prospective, pragmatic, single-center, double-arm study assessed the impact of the Vivovitals diabetes platform on glycemic control in 78 adults aged ≥18 years with HbA1c levels of ≥7.5% (58 mmol/mol) at baseline. The participants were randomized into 2 groups. The control group received usual clinical care, whereas the intervention group was provided with a smartphone-linked telehealth application, a preconfigured glucometer, and access to a glycemic reading diary. The blood glucose levels of the intervention group were transmitted to the providers daily. Patients whose blood glucose level was <70 mg/dL or >180mg/dL were contacted, and modifications were made to their diet and medication. The 2 groups were compared at the baseline and at 12 weeks using nonparametric tests, with P <.05 considered statistically significant.ResultsOver 12 weeks, the average HbA1c level in the control group reduced by 0.474% (P = .533; 95% CI, ?0.425 to ?0.523), whereas the average HbA1c level in the intervention group reduced by 1.70% (P = .002; 95% CI, ?1.02 to ?2.39). The estimated treatment difference was expressed using Cohen d, which yielded 0.62. After 12 weeks, the HbA1c values between the control and intervention groups were statistically significant (P = .001).ConclusionThe use of the Vivovitals platform may help to improve glycemic control among individuals with type 2 diabetes mellitus. |
| |
| Keywords: | digital technology self-management education glycemic control type II diabetes hemoglobin A1c (HbA1c) blood glucose monitoring BG"} {"#name":"keyword" "$":{"id":"kwrd0045"} "$$":[{"#name":"text" "_":"blood glucose CGM"} {"#name":"keyword" "$":{"id":"kwrd0055"} "$$":[{"#name":"text" "_":"continuous glucose monitoring ETD"} {"#name":"keyword" "$":{"id":"kwrd0065"} "$$":[{"#name":"text" "_":"estimated treatment difference |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
